COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of CellCept for Advanced Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00997958
Recruitment Status : Completed
First Posted : October 20, 2009
Last Update Posted : April 25, 2014
Information provided by (Responsible Party):
Robert L. Fine, Columbia University

Brief Summary:
Mycophenolate Mofetil (CellCept) is an FDA approved, well tolerated, oral medication used to prevent the body's immune system from attacking transplanted organs. It has never been studied in patients with pancreatic cancer but some preliminary studies have shown that it may antagonize tumor growth. The goals of this study are to find out how much of this drug can safely be taken by patients with advanced pancreatic cancer and to assess the variation of the level of the drug in the blood. Patients will take the drug twice a day at a given dose and the safety of the drug will be monitored through patient symptoms and blood tests. The disease burden will be assessed by radiographic studies at the beginning and end of the study. The patient will take the drug for a total of eight weeks.

Condition or disease Intervention/treatment Phase
Pancreatic Cancer Drug: Mycophenolate mofetil Phase 1

Detailed Description:
Mycophenolate Mofetil (CellCept) is a prodrug whose active metabolite, mycophenolic acid (MPA), acts as an immune suppressant by inhibiting de novo guanosine synthesis. CellCept is FDA approved to prevent rejection of transplanted organs. It is well tolerated, orally dosed, and has some known antitumor effects. It has never been studied in pancreatic cancer and the maximum tolerated dose is not known. In vitro studies in our lab with human pancreatic cancer lines found that MPA was a potent inhibitor of pancreatic cancer cell growth and induced apoptosis. The objectives of this study are to identify the maximum tolerated dose of CellCept in patients with advanced pancreatic cancer that have failed at least two prior chemotherapy regimens and assess its pharmacokinetics.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of CellCept for Advanced Pancreatic Cancer
Study Start Date : June 2004
Actual Primary Completion Date : October 2007
Actual Study Completion Date : January 2009

Arm Intervention/treatment
Experimental: CellCept
Administered in tablet form twice daily one hour after eating.
Drug: Mycophenolate mofetil

Dose escalation increasing successively from 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, and 5.0 grams p.o. bid.

Each patient will be treated for eight weeks (56 days).

Primary Outcome Measures :
  1. Identification of maximum tolerated dose of CellCept in patients with advanced pancreatic cancer [ Time Frame: 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed adenocarcinoma of pancreas.
  • Disease stage IV, locally advanced and/or metastatic.
  • Measurable disease: Any mass reproducibly measurable in two perpendicular diameters by x-ray, physical examination, CT or MRI scan.
  • The following lesions conventionally are not considered measurable:

    • CNS lesions
    • Blastic or lytic bone lesions (which will be documented and followed)
    • Radiated lesions unless progression after RT is documented
  • Ineligible for other high priority national or institutional studies.
  • Prior therapy allowed:

    • Chemotherapy (at least one prior regimen)
    • > 3 weeks since last chemotherapy
    • > 3 weeks since surgery
    • ≥ 4 weeks since RT
  • Non pregnant, non lactating women with a negative serum α-HCG test within one week of starting the study, AND
  • Must be willing to consent to the use of two forms of contraception (at least one barrier) if of childbearing potential while on trial and six weeks after CellCept has been stopped.
  • Clinical Parameters:

    • Life expectancy ≥ 3 months
    • Age 18 to 70 years
    • Brain CT or MRI no visible metastases
    • Performance status 0-2 (ECOG- see appendix B)
    • HIV negative or never tested
  • Required initial laboratory data:

    • Normal
    • White cell count ≥3000 cells / μl
    • Platelet count ≥100,000 platelets / μl
    • BUN ≤1.5 x normal 20 mg/dl
    • Creatinine ≤1.5 x normal 1.0 mg/dl
    • Total Bilirubin ≤3.0 mg/dl
    • AST, ALT ≤3.0 x normal 38 U/L
    • Alkaline Phosphatase ≤3.0 x normal 96 U/L
    • Albumin ≥2.5 g/dl
  • Informed Consent: Each patient must be completely aware of the nature of his/her disease process and must willingly give written consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, adverse effects, risks, and discomforts.
  • Prior malignancy in last 5 years: The cancer must be curatively treated carcinoma in situ of the cervix or skin cancer.
  • No serious medical or psychiatric illness preventing informed consent or intensive treatment (e.g., serious infection).
  • Absence of concurrent treatment with cholestyramine, acyclovir, cyclosporine, or antacids with magnesium or aluminum hydroxides because of their effects on drug metabolism and serum levels of MPA.
  • Absence of active serious digestive system disease as defined at the discretion of the Principal Investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00997958

Layout table for location information
United States, New York
Columbia University Medical Center
New York, New York, United States, 10032
Sponsors and Collaborators
Columbia University
Layout table for investigator information
Principal Investigator: Robert L Fine, MD Columbia University
Layout table for additonal information
Responsible Party: Robert L. Fine, Associate Professor of Hematology and Oncology, Columbia University Identifier: NCT00997958    
Other Study ID Numbers: AAAA1127
First Posted: October 20, 2009    Key Record Dates
Last Update Posted: April 25, 2014
Last Verified: April 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Mycophenolic Acid
Antibiotics, Antineoplastic
Antineoplastic Agents
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action